IP Verse

Combination Therapies For Cancer - EP3003316

The patent EP3003316 was granted to Glaxosmithkline on Jul 22, 2020. The application was originally filed on May 28, 2014 under application number EP14805105A. The patent is currently recorded with a legal status of "Revoked".

EP3003316

GLAXOSMITHKLINE
Application Number
EP14805105A
Filing Date
May 28, 2014
Status
Revoked
Jun 2, 2023
Grant Date
Jul 22, 2020
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

PAJAROApr 21, 2021ALTADMISSIBLE

Patent Citations (4) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
INTERNATIONAL-SEARCH-REPORTUS2012196879
INTERNATIONAL-SEARCH-REPORTWO2013019906
OPPOSITIONUS10010608
OPPOSITIONWO2014193898

Non-Patent Literature (NPL) Citations (18) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
INTERNATIONAL-SEARCH-REPORT- KLINAC ET AL., "Advances in Personalized Targeted Treatment of Metastatic Melanoma and Non- Invasive Tumor Monitoring", FRONT ONCOL., (2013), vol. 3, pages 1 - 16, XP055298647
OPPOSITION- Anonymous, "A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475- 022/KEYNOTE-022)", ClinicalTrials.gov Identifier: NCT02130466, (20200324), ClinicalTrials.gov Identifier: NCT02130466, URL: https://clinicaltrials.gov/ct2/show/NCT02130466, (20220920), XP055962761-
OPPOSITION- Anonymous, "Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone NCT02027961", ClinicalTrials.gov, (20190517), ClinicalTrials.gov, URL: https://clinicaltrials.gov/ct2/show/study/NCT02027961, (20220920), XP055962756-
OPPOSITION- Anonymous, "Phase II/III Trial of MK -3475 in Patients with NSCLC Currently Enrolling", merck, (20131029), merck , URL: https://www.merck.com/news/merck-announces-presentation-of-interim-data-from-phase-1 b-study-of-mk-34 75-investigational-anti-pd-1-immunotherap, (20220920), XP055962752-
OPPOSITION- Anonymous, "Study of Pembrolizumab (MK-3475) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001/KEYNOTE-001) (KEYNOTE-001)", clinicaltrials.gov, (20191213), XP055962730-
OPPOSITION- Elie Dolgin, "MELANOMA DRUG JOINS BREAKTHROUGH CLUB ", NATURE MEDICINE, (20130424), XP055962682-
OPPOSITION- MELINDA YUSHAK et al., "Advances in the Systemic Treatment of Metastatic Melanoma", Cancer Network; Oncology (Williston Park, (20130515), vol. 27, no. 5, pages 374 - 381, XP055962689-
OPPOSITION- FLAHERTY KEITH T, ET AL, "Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations", The New England journal of medicine, Massachusetts Medical Society, US, US , (20121101), vol. 367, no. 18, doi:10.1056/NEJMoa1210093, ISSN 0028-4793, pages 1694 - 1703, XP002725869
OPPOSITION- Heinzerling Lucie, Eigentler Thomas K., Fluck Michael, Hassel Jessica C., Heller-Schenck Daniela, Leipe Jan, Pauschinger Matthias, Vogel Arndt, Zimmer Lisa, Gutzmer Ralf, "Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management", ESMO open : cancer horizons, European Society for Medical Oncology, London, London , vol. 4, no. 3, doi:10.1136/esmoopen-2019-000491, ISSN 2059-7029, XP055962702
OPPOSITION- D. T. Frederick, A. Piris, A. P. Cogdill, Z. A. Cooper, C. Lezcano, C. R. Ferrone, D. Mitra, A. Boni, L. P. Newton, C. Liu, W. Peng, R. J. Sullivan, D. P. Lawrence, F. S. Hodi, W. W. Overwijk, G. Lizee, G. F. Murphy, P. Hwu, K. T. Flaherty, D. E. Fisher, J. A. Wargo, "BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma", Clinical Cancer Research, Association for Cancer Research, US, US, (20130301), vol. 19, no. 5, doi:10.1158/1078-0432.CCR-12-1630, ISSN 1078-0432, pages 1225 - 1231, XP055568357
OPPOSITION- Mustafa Khasraw, David A. Reardon, Michael Weller, John H. Sampson, "PD-1 Inhibitors: Do they have a Future in the Treatment of Glioblastoma?", Clinical Cancer Research, Association for Cancer Research, US, US, (20201015), vol. 26, no. 20, doi:10.1158/1078-0432.CCR-20-1135, ISSN 1078-0432, pages 5287 - 5296, XP055750959
OPPOSITION- Asad Javed, David Arguello, Curtis Johnston, Zoran Gatalica, Mizue Terai, Ryan M Weight, Marlana Orloff, Michael J Mastrangelo, Takami Sato, "PD-L1 expression in tumor metastasis is different between uveal melanoma and cutaneous melanoma", Immunotherapy, Future Medicine Ltd., GB, GB , (20171201), vol. 9, no. 16, doi:10.2217/imt-2017-0066, ISSN 1750-743X, pages 1323 - 1330, XP055750914
OPPOSITION- Dragana Klinac, Elin S. Gray, Michael Millward, Mel Ziman, "Advances in Personalized Targeted Treatment of Metastatic Melanoma and Non-Invasive Tumor Monitoring", Frontiers in Oncology, vol. 3, doi:10.3389/fonc.2013.00054, XP055298647
SEARCH- Anonymous, "Combination Therapy Approved for Melanoma", doi:10.1158/2159-8290.CD-NB2014-013, (20140130), page 262, CANCER DISCOVERY, URL: http://cancerdiscovery.aacrjournals.org/content/4/3/262.2.full-text.pdf, (20161220), XP002765041 [YP] 1-4,6,8,10,12-19 * middle column, 1st paragraph *-
SEARCH- Anonymous, "Lambrolizumab induces advanced melanoma regression", (20130607), The Lancet, URL: http://www.thelancet.com/oncology, (20161206), XP002765043 [YP] 1-4,6,8,10,12-19 * column l, paragraph 1 * * right-hand column, last paragraph *-
SEARCH- DĂ–MLING ALEXANDER ET AL, "Programmed death-1: therapeutic success after more than 100 years of cancer immunotherapy.", ANGEWANDTE CHEMIE (INTERNATIONAL ED. IN ENGLISH), (20140224), vol. 53, no. 9, ISSN 1521-3773, pages 2286 - 2288, XP002765044 [YP] 1-4,6,8,10,12-19 * page 2287, column r, paragraph 1 * * table 1 *-
SEARCH- MENZIES ALEXANDER M ET AL, "Dabrafenib and Trametinib, Alone and in Combination for BRAF-Mutant Metastatic Melanoma", CLINICAL CANCER RESEARCH, (201404), vol. 20, no. 8, pages 2035 - 2043, XP002765042 [YP] 1-4,6,8,10,12-19 * page 2035, abstract *-
SEARCH- OMID HAMID ET AL, "Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma", NEW ENGLAND JOURNAL OF MEDICINE, (20130711), vol. 369, no. 2, doi:10.1056/NEJMoa1305133, ISSN 0028-4793, pages 134 - 144, XP055182016 [YP] 1-4,6,8,10,12-19 * page 134, abstract * * page 143, column r, paragraph 1 *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents